Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* ≥60 years old individuals with full civil capacity.~* Clinically confirmed body temperature of \<37.3°C before enrolling in this study.~* Able and willing to participate in the study plan during the entire study and follow-up period.~* Capable of understanding the study procedures, willing to sign the informed consent form, and able to comply with the requirements of the clinical study protocol.~* Inclusion criteria for patients with hypertension and/or diabetes: Hypertension and/or diabetes definitively diagnosed by a community-level or higher medical institution. Patients with hypertension: systolic pressure \<160 mmHg and diastolic pressure \<100 mmHg on the day of immunization achieved by lifestyle adjustment and/or drug treatment; patients with diabetes: fasting glucose ≤13.9 mmol/L on the day of (or within 3 days before) immunization achieved by lifestyle adjustment and/or drug treatment.~Exclusion Criteria:~* Previously confirmed or asymptomatic COVID-19 patient.~* Has been immunized with a SARS-CoV-2 vaccine.~* Illiterate.~* Known allergy to any ingredient (including excipient) of this product.~* Received non-specific immunoglobulin injection within 1 month before enrollment.~* Received a live attenuated vaccine within 1 month before immunization or other vaccine within 14 days before immunization.~* Previous serious allergy to vaccine (e.g., acute allergic reaction, urticaria, angioedema, and dyspnea).~* Has uncontrolled epilepsy and other progressive neurological disorders; history of Guillain-Barré syndrome.~* Severe respiratory disorders, severe hepatic and renal diseases, malignancies, and various acute diseases or acute onset of chronic diseases.~* Diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, or other autoimmune diseases.~* Definitively diagnosed with thrombocytopenia or history of other coagulation disorders that may cause subcutaneous injection to be contraindicated.~* Currently experiencing acute complications (ketoacidosis, hyperosmolar state, lactic acidosis, etc.) of diabetes; or within 2 weeks after recovery from these complications.~* Other physical conditions judged by the investigator that render the patient unsuitable for participation in the clinical study.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Hypertension group (Type: EXPERIMENTAL): Hypertension group will enroll 330 subjects with hypertension (aged 60 years or older).
- Diabetes group (Type: EXPERIMENTAL): Diabetes group will enroll 330 subjects with diabetes (aged 60 years or older).
- Combined Diseases group (Type: EXPERIMENTAL): Combined Diseases group will enroll 300 subjects with both hypertension and diabetes (aged 60 years or older).
- Healthy people group (Type: ACTIVE_COMPARATOR): Healthy people group will enroll 480 subjects with no medical history of hypertension or diabetes (aged 60 years or older).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete